Renascience Inc. Logo

Renascience Inc.

A drug discovery venture developing medicines for diseases of tissue aging.

4889 | T

Overview

Corporate Details

ISIN(s):
JP3981100005
LEI:
Country:
Japan
Address:
仙台市青葉区星陵町2−1

Description

Renascience Inc. is a drug discovery venture originating from Tohoku University. The company focuses on the research and development of various medical modalities, including pharmaceuticals, medical devices, and artificial intelligence (AI) applications. A primary area of its R&D is the study of cellular senescence at the molecular level to develop novel medicines for diseases associated with tissue aging. While initially founded with a focus on kidney disease, Renascience collaborates with academic institutions and corporate partners to advance its diverse R&D pipelines through clinical trials.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-11-14 07:36
半期報告書-第26期(2024/04/01-2025/03/31)
Japanese 288.9 KB
2024-06-28 04:56
臨時報告書
Japanese 24.5 KB
2024-06-28 04:32
内部統制報告書-第25期(2023/04/01-2024/03/31)
Japanese 22.7 KB
2024-06-28 04:26
確認書
Japanese 8.7 KB
2024-06-28 04:24
有価証券報告書-第25期(2023/04/01-2024/03/31)
Japanese 3.5 MB
2024-05-27 10:10
臨時報告書
Japanese 22.4 KB
2024-02-08 07:46
確認書
Japanese 8.7 KB
2024-02-08 07:45
四半期報告書-第25期第3四半期(2023/10/01-2023/12/31)
Japanese 235.8 KB
2023-11-09 07:03
確認書
Japanese 8.7 KB
2023-11-09 07:02
四半期報告書-第25期第2四半期(2023/07/01-2023/09/30)
Japanese 259.6 KB
2023-08-10 08:05
確認書
Japanese 8.7 KB
2023-08-10 08:02
四半期報告書-第25期第1四半期(2023/04/01-2023/06/30)
Japanese 229.5 KB
2023-06-30 04:06
内部統制報告書-第24期(2022/04/01-2023/03/31)
Japanese 22.7 KB
2023-06-30 04:04
確認書
Japanese 8.7 KB
2023-06-30 04:03
有価証券報告書-第24期(2022/04/01-2023/03/31)
Japanese 3.7 MB

Automate Your Workflow. Get a real-time feed of all Renascience Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Renascience Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Renascience Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Access Bio, Inc. Logo
Develops and manufactures in vitro diagnostic solutions for infectious diseases.
United States of America
950130
ACHIEVE LIFE SCIENCES, INC. Logo
A late-stage pharmaceutical company developing a treatment for nicotine dependence.
United States of America
ACHV
AC Immune SA Logo
Biopharmaceutical firm developing precision medicine for neurodegenerative diseases.
United States of America
ACIU
Aclaris Therapeutics, Inc. Logo
Clinical-stage biopharmaceutical company developing drugs for immuno-inflammatory diseases.
United States of America
ACRS
Acrivon Therapeutics, Inc. Logo
Clinical-stage biopharma using proteomics to develop precision oncology therapies.
United States of America
ACRV
Acticor Biotech Logo
Develops treatments for thrombotic diseases, focusing on acute ischemic stroke.
France
ALACT
Actinium Pharmaceuticals, Inc. Logo
Clinical-stage company developing targeted radiotherapies for difficult-to-treat cancers.
United States of America
ATNM
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing therapies for cancers with high unmet needs.
United States of America
ACTU
AcuCort AB Logo
Develops user-friendly drug formulations for severe and acute allergic reactions.
Sweden
ACUC
Acumen Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing targeted therapies for Alzheimer's disease.
United States of America
ABOS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.